2 articles
Max Hodak's Science Corporation secured $230 million in Series C funding to commercialize PRIMA, a photovoltaic retinal implant restoring vision for geographic atrophy patients.
Max Hodak's Science Corporation secures $230 million to commercialize its retinal BCI implant, marking one of the largest funding rounds in neurotechnology as vision restoration approaches clinical reality.
Get the latest BCI news, breakthroughs, and market moves delivered to your inbox.
No spam. Unsubscribe anytime. We respect your privacy.